Literature DB >> 18596856

Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria.

Matthew R Weir1.   

Abstract

Objective measures of cardiovascular disease are often lacking until patients develop symptoms associated with either coronary, cerebral or peripheral vascular disease. Estimating risk for cardiovascular disease is often based on classic Framingham Heart Study criteria, such as age, gender, blood pressure, cholesterol, glucose levels and family history. Moreover, there is a well described continuous relationship between blood pressure, cholesterol, and glucose and risk for cardiovascular events. Estimating GFR, using simple formulae, and screening quantitatively for albuminuria may provide an important opportunity for identifying patients at increased risk for cardiovascular events. These safe, simple and cost-effective measures of estimating cardiovascular disease risk can be used not only to estimate cardiovascular disease burden, but also to gauge the adequacy of response to cardiovascular risk-reducing therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18596856      PMCID: PMC2394694     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  24 in total

1.  Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects.

Authors:  P Clausen; J S Jensen; G Jensen; K Borch-Johnsen; B Feldt-Rasmussen
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 8.  Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease.

Authors:  R Pedrinelli; G Dell'Omo; G Penno; M Mariani
Journal:  Vasc Med       Date:  2001-11       Impact factor: 3.239

Review 9.  Microalbuminuria and cardiovascular disease.

Authors:  Matthew R Weir
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-14       Impact factor: 8.237

10.  Endothelial dysfunction and inflammation in asymptomatic proteinuria.

Authors:  Karen E Paisley; Martin Beaman; John E Tooke; Vidya Mohamed-Ali; Gordon D O Lowe; Angela C Shore
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.